Medical Condition News

RSS

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Xoft to showcase a variety of investigational IORT oncology applications at ACS Annual Congress

Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

The Hallowell Centers include beneficial exercises in treatment of ADHD

New brain research is unlocking long-standing mysteries, explaining how the brain trains itself and how human beings develop their superior cognitive skills. New scanning tools (FMRI, SPECT, QEEG, etc.) are advancing neurology's understanding of a process called neuroplasticity and shedding light on a simple looking balance and movement regimen used since 1982 by developmental specialists to treat people with ADHD, Dyslexia and other learning differences.

12 Oct 2009

Holistic care needed for people with Alzheimer's disease and dementia

Whilst cognitive function can be improved by the medicines currently available for the treatment of dementias, the positive effects of improved socialibility, initiative and motivation on the patient and their carer as well as their capability of coping with everyday life should not be overlooked says a research report published by the Pharmacy Practice Research Trust (the Trust).

12 Oct 2009

Rice consumption improves overall diet and reduces obesity and Type II diabetes

According to recent research published in the October issue of the Journal of the American Dietetic Association (JADA), eating rice helps improve overall diet and potentially reduces the risk for many chronic diseases, including obesity, cardiovascular disease and Type II diabetes.

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

GE Healthcare launches global initiative to celebrate 10th anniversary of digital mammography

GE Healthcare (NYSE:GE) wishes to issue the following update and correction to its release NewsItemID 20090923005515 (GE-HEALTHCARE) "GE Healthcare Launches Global Initiative to Celebrate the 10th Anniversary of Digital Mammography" issued September 23, 2009/

12 Oct 2009

The third “Exciting Biologies” meeting focuses on “Biology In Balance”

In a continuing series called “Exciting Biologies” Cell Press, Massachusetts General Hospital and La Fondation Ipsen collaborate to offer annual meetings designed to highlight emerging intersections in biomedical research and promote interactions between scientists from converging disciplines. This third meeting, held in Buenos Aires between the 8th and 10th of October, focused on “Biology in Balance”.

12 Oct 2009

Study finds that stranger homicide by people with schizophrenia rare

International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events

12 Oct 2009

First evidence that personalized medicine leads to better outcomes

A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.

12 Oct 2009

COPD Management Program for South Region TRICARE beneficiaries

Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc., announced today an additional benefit available for South Region TRICARE beneficiaries. The Chronic Obstructive Pulmonary Disease (COPD) Management Program offers telephonic education and coaching by dedicated registered nurses.

12 Oct 2009

New journal focuses on therapeutic hypothermia and its applications in cardiology and neurotrauma

Therapeutic Hypothermia, a new online open access peer-reviewed journal, will focus on medical treatment which lowers a patient's body temperature to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow.

12 Oct 2009

Vaccination against HPV will help decrease cervical cancer death rate in India

Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region, according to data presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting.

12 Oct 2009

Federal stimulus funds for comparative-effectiveness research in cancer

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

12 Oct 2009

U.S. women with RA feel less self-confident in their sex-life, reveals survey

A new survey of U.S. women living with rheumatoid arthritis (RA) published today reveals that RA has a clear emotional impact on people living with the disease, with loss of self-confidence seen in their sex lives, in the workplace, and in their social lives.

12 Oct 2009

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Fibrocell Science, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults.

12 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

Researchers find how KEAP1 tumor suppressor works

A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.

12 Oct 2009